Metallurgical coal producer Bens Creek Group (LON: BEN) reported a significant loss for the year to March 2023. Production is increasing and it should help the company move into profit, but there is still a lot to prove.
Bens Creek has a coal mine in West Virginia that produces coal for steel production. There were delays in ramping up production that hit the figures last year.
Last year’s revenues were $42.2m, while the pre-tax loss was $24.7m. In its initial research published in January, WH Ireland forecast revenues of $48m and a pre-tax profit of $1.4m.
There is a difference in the revenue...
AIM movers: Scirocco Energy completes disposal and disappointing third quarter for Audioboom
Scirocco Energy (LON: SCIR) has completed the disposal of its 25% stake in the Ruvuma project and it has received the $2.54m completion payment. A further $3m is payable on final investment decision, up to $8m net revenue share and contingent consideration of $2m based on production levels. The share price jumped 26.7% to 0.475p.
Mosman Oil & Gas (LON: MSMN) has signed a farm-in agreement with Greenvale Gold to fund seismic and drilling on the EP 145 project in the Northern Territory of Australia. Mosman will retain a 25% interest if a four-year work programme is completed. There is an initial payment to Mosman of A$160,000. The share price increased 34.9% to 0.029p.
Drilling has been restarted at the Tai-3 well in Tanzania after Helium One Global (LON: HE1) sourced a replacement rig component from the US. The share price improved 16.3% to 5.7p.
Telecoms billing software provider Cerillion (LON: CER) has beaten forecasts again. There has been buoyant demand from existing customers, even though there have not been any large contracts signed recently. A pre-tax profit of £15.3m is forecast for the year to September 2023. The share price has fallen in recent weeks, but it recovered 9.43% to 1160p.
FALLERS
Two executives of T42 IoT Tracking Solutions (LON: TRAC) have subscribed £12,600 for shares at 3.5p each. Two other directors have taken shares in lieu of salary. This provides additional working capital for the tracking products company. Even so, the share price fell 10.1% to 2.75p.
Crossword Cybersecurity (LON: CCS) is raising £230,000 from unsecured, convertible loans, taking the total loans raised to £2.245m out of an authorised £2.5m. The share price slipped 8.57% to 8p.
Audioboom (LON: BOOM) reports third quarter revenues of $14m and made a loss because of weak advertising demand. The podcast platform operator is expected to generate revenues of $19m and a positive EBITDA in the fourth quarter. Cavendish had expected a 2023 profit, but it has downgraded to a £1.9m loss, compared with a £3.2m pre-tax profit in 2022. A return to profit is expected in 2024. The share price dipped 5.56% to 170p.
Anglo Asian Mining (LON: AAZ) produced 5,300 gold equivalent ounces in the third quarter, down from 14,300 ounces in the same period last year due to the suspending of flotation and agitation leaching operations. Full year production guidance is 30,000-34,000 ounces. Discussions continue for the restart of production at Gedabek. Net cash declined to $1.6m. The share price fell 3.88% to 49.5p.
FTSE 100 edges higher ahead of US earnings season
The FTSE 100 edged higher on Monday in tentative trade as investors awaited further geopolitical developments and geared up for the US earnings season.
The FTSE 100 was up 0.3% to 7,624 at the time of writing on Monday.
“A mute start to the week for European indices suggests a sense of nervousness, particularly as the US reporting season gets underway and investors worry about a cautious tone in corporate outlooks,” said Russ Mould, investment director at AJ Bell.
“The FTSE 100 was flat…with strength in retail and mining stocks offset by weakness in pharmaceuticals amid negative read-across from Pfizer’s weak update.”
Investors are preparing for earnings updates from US companies including Tesla, Netflix, Goldman Sachs and Morgan Stanley this week.
Geopolitical risks
Natural resources companies were among the FTSE 100 top gainers on Monday as the human tragedy in the Middle East supported commodity prices.
“As risk-off sentiment has been spreading, investors have been seeking more defensive positions amid fears of conflict escalating in the Middle East,” said Susannah Streeter, head of money and markets, Hargreaves Lansdown.
“Investors are braced for volatility ahead amid fears that Hezbollah militants could attack Israel over its operations in Gaza as forces ready for invasion.”
BP and Shell added a significant number of points to the FTSE 100.
St James’s Place was the top riser, up 3%, with a small bounce back from Friday’s crash.
Ocado shares were down 5.3% at the time of writing on Monday and were the biggest faller.
“Ocado fell after a broker downgrade on the stock, citing concerns about delays to rolling out new fulfilment centres and competition for warehouse automation systems intensifying,” said Mould.
North American promise for Tristel
Disinfection products supplier Tristel (LON: TSTL) was more profitable than forecast and there is little contribution from North America yet.
NHS activity recovered so UK growth was fastest, but overseas sales were 17% ahead. In the year to June 2023, revenues were 16% higher at £36m, while adjusted pre-tax profit improved from £4.5m to £6.2m. Net cash was £9.5m at the end of June 2023. The dividend was raised by 10% to 10.5p/share.
Tristel is still awaiting regulatory approvals for newer Cache hospital surface disinfection products, so most of the growth was in the hospital medical device decontamination division.
Manufacturing capacity has been validated in the US and sales have commenced for the products that have FDA approval. The initial focus in the US is the ultrasound probes market and further product approvals will expand the potential market into ophthalmic and ear, nose and throat devices.
Cavendish forecasts a 2023-24 pre-tax profit of £7.6m, and then £10m the following year. The share price rose 5.06% to 415p, which puts the shares on 30 times prospective earnings, falling to 25.
Premier African Minerals investors await key production figures and lithium grades
Premier African Minerals has been very quiet when it comes to the grades of lithium at their Zulu project in Zimbabwe. Under the terms of the offtake agreement with their Chinese partner Canmax, Premier African Minerals is required to supply lithium with a grade close to 6%.
Throughout the Canmax saga, attention was focused entirely on contract negotiations and whether Premier African Minerals would be forced to repay the prepayment amount.
Canmax proved to be supportive of Premier African Minerals and was forthcoming with renegotiating their offtake agreement. The terms, however, leave Premier African Minerals little room for error.
The company must achieve 1,000-tonne production per month by the end of November or face penalties including cash payments – and even the transfer of an interest in the Zulu project to Canmax.
While the focus has been on the production figures, we are yet to hear anything material on the grade of the offtake since operations recommenced at Zulu.
Earlier in 2023, Premier African Minerals said they were unable to produce the required lithium grades above 6% at Zulu without the use of reagents.
Premier must produce lithium with grades close to 6% under the terms of their offtake agreement. Failure to do so at the specified quantity will trigger penalties.
Grades can be released alongside shipment announcements and any upcoming announcement will be crucial for Premier African Minerals shares.
For example, Core Lithium announced its first lithium shipment from the Finnis project had a 5.6% grade shortly before the shipment was made in May this year. Core Lithium shares reacted positively in the immediate period.
Sayona Mining enjoyed a pop after announcing the production of 30,000 tonnes of saleable lithium concentrate at 5.5% before shipments commenced over the summer.
Premier African Minerals shares have been stuck in a tight range since the new agreement was inked with Canmax. The announcement of lithium grades will likely be a catalyst for PREM shares to break out of this range.
Expect a sharp decline in PREM shares if the Zulu grades are less than 5%. However, if this is the case, it is unlikely Premier African Minerals will reveal the exact grades.
Premier African Minerals shares are down 52% over the past six months.
Aquis new admission: Mydecine Innovations
Mydecine Innovations has added an Aquis quotation to is listing on the Canadian Stock Exchange. The biotech and life sciences company believes that coming to Aquis will increase exposure in the UK and Europe. The main focus is addiction, PTSD and other mental conditions.
There have been no trades in the shares on Aquis since the introduction. The share price has stayed at 10p. The lack of liquidity is a concern.
==========
Mydecine Innovations (LON: MYIG)
Biotech and life sciences
Market: Aquis / Access
Flotation date: 10 October 2023
Introduction price: 10p
Amount raised: nil
Market capitalisation: £4.52m
Corporate adviser: Novum Securities
==========
What does it do?
British Columbia registered Mydecine Innovations is developing mental health treatments. The second generation molecules developed by the company are showing improvements over first generation psychedelic treatments.
The company has a Health Canada scheduled 1 drugs and substances dealer’s licence. There are four lead drug candidates that cover more than one area each. These cover areas such as smoking cessation, PTSD, anxiety and substance use disorder. There are ten pending patents.
A pre-clinical team is working with the University of Alberta to get the molecules through the Investigational New Drug enabling stage. Human clinical studies could commence in 2024.
There are other research partnerships with Imperial College London, Johns Hopkins University, and Macquarie University
Financials
There are no revenues. There was a $5.14m cash outflow from operating activities in the six months to June 2023 was slightly lower than in the previous first half. The main costs are consulting fees. During the period there was $4.625m raised from issuing shares. Net debt is $5.2m at the end of June 2023.
In 2022, Mydecine Innovations received shares and warrants in Pangenomic Health Inc for the sale of virtual health platform Mindleap. These have been sold for $1.8m at a total loss of $4.9m.

